Complement 5a receptor-mediated neutrophil dysfunction is associated with a poor outcome in sepsis

Cellular and Molecular Immunology

Volumn 13, Issue 1, 2016, Pages 103-109

  Xu, Ruonan ^a   Lin, Fang ^a   Bao, Chunmei ^a   Huang, Huihuang ^a   Ji, Chengcheng ^a   Wang, Siyu ^a   Jin, Lei ^a   Sun, Lijian ^a   Li, Ke ^a   Zhang, Zheng ^a   Wang, Fu Sheng ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

complement 5a; complement 5a receptor; neutrophil; prognosis; sepsis

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT 5L2; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; INTERLEUKIN 8; UNCLASSIFIED DRUG; C5AR1 PROTEIN, HUMAN; CHEMOKINE RECEPTOR; GPR77 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL FUNCTION; CELLULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; IN VITRO STUDY; MALE; NEUTROPHIL DYSFUNCTION; PROGNOSIS; PROTEIN FUNCTION; SEPSIS; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UPREGULATION; AGED; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; NEUTROPHIL; PATHOLOGY; PRIMARY CELL CULTURE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; COMPLEMENT C5A; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; NEUTROPHILS; PRIMARY CELL CULTURE; PROGNOSIS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, CHEMOKINE; SEPSIS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84954199278     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2014.136     Document Type: Article

References (24)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D et al. SCCM/ESICM/ACCP/ATS/SI:2001SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
2. Balk RA. Severe sepsis and septic shock. Crit Care Clin 2000; 16: 179-192.
3. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001; 29: S109-S116.
4. Andonegui G, Zhou H, Bullard D, Kelly MM, Mullaly SC, McDonald B et al. Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection. J Clin Invest 2009; 119: 1921-1930.
5. Brown KA, Treacher DF. Neutrophils as potential therapeutic targets in sepsis. Discov Med 2006; 6: 118-122.
6. Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB et al. C5L2, a nonsignaling C5A binding protein. Biochemistry 2003; 42: 9406-9415.
7. Li R, Coulthard LG, Wu MC, Taylor SM, Woodruff TM. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J 2013; 27: 855-864.
8. Huber-Lang M, Sarma JV, Rittirsch D, Schreiber H, Weiss M, Flierl M et al. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J Immunol 2005; 1174: 1104-1110.
9. Gressner OA, Koch A, Sanson E, Trautwein C, Tacke F. High C5a levels are associated with increased mortality in sepsis patients-no enhancing effect by actin-free Gc-globulin. Clin Biochem 2008; 41:974-980.
10. Guo RF, Huber-Lang M, Wang X, Sarma V, Padgaonkar VA, Craig RA et al. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000; 106: 1271-1280.
11. Bone RC, Balk RA, Cerra FB. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
12. Poehlmann H, Schefold JC, Zuckermann-Becker H, Volk HD, Meisel C. Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care 2009; 13: R119.
13. Solomkin JS, Jenkins MK, Nelson RD, Chenoweth D, Simmons RL. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery 1981; 90: 319-327.
14. Guo RF, Riedemann NC, Bernacki KD, Sarma VJ, Laudes IJ, Reuben JS et al. Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J 2003; 17: 1889-1891.
15. Unnewehr H, Rittirsch D, Sarma JV, Zetoune F, Flierl MA, PerlMet al. Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J Immunol 2013; 1908: 4215-4225.
16. Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, Guo RF et al. Complement-induced impairment of innate immunity during sepsis. J Immunol 2002; 169: 3223-3231.
17. Kim H, Erdman LK, Lu Z, Serghides L, Zhong K, Dhabangi A et al. Functional roles for C5a and C5aR, but not C5L2, in the pathogenesis of human and experimental cerebral malaria. Infect Immun 2014; 82: 371-379.
18. Wang R, Lu B, Gerard C, Gerard NP. Disruption of the complement anaphylatoxin receptor C5L2 exacerbates inflammation in allergic contact dermatitis. J Immunol 2013; 191: 4001-4009.
19. Guo RF, Riedemann NC, Laudes IJ, Ward PA. Altered neutrophil trafficking during sepsis. J Immunol 2002; 169: 307-314.
20. Riedemann NC, Guo RF, Ward PA. A key role of C5a/C5aR activation for the development of sepsis. J Leukoc Biol 2003; 74: 966-970.
21. Conway MA, Kefala K, Wilkinson TS, Dhaliwal K, Farreii L, Walsh T et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med 2009; 180: 19-28.
22. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghö ner A, Vidacek D, Siewert E et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005; 42: 195-201.
23. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P et al. Monocyte deactivation in septic patients: restoration by IFNgamma treatment. Nat Med 1997; 3: 678-681.
24. Conway MA, Anderson N, Brittan M, Wilkinson TS, McAuley DF, Antonelli J et al. Combined dysfunctions of immune cells predict nosocomial infection in critically ill patients. Br J Anaesth 2013; 111:778-787.